LEADER 01790oam  2200493   450 
001 9910715017103321
005 20210402093054.0
035   $a(CKB)5470000002507836
035   $a(OCoLC)1224541481$z(OCoLC)1227256921
035   $a(EXLCZ)995470000002507836
100   $a20201130d2020      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aFairness in Orphan Drug Exclusivity Act $ereport (to accompany H.R. 4712)
210  1$a[Washington, D.C.] :$c[U.S. Government Publishing Office],$d[2020]
215   $a1 online resource (11 pages)
225 1 $aReport / 116th Congress, 2d session, House of Representatives ;$v116-572
300   $a"November 16, 2020."
320   $aIncludes bibliographical references.
517   $aFairness in Orphan Drug Exclusivity Act 
606   $aDrug development$xEconomic aspects$zUnited States
606   $aBuprenorphine$xTherapeutic use$zUnited States
606   $aOrphan drugs$xGovernment policy$zUnited States
606   $aDrugs$xPrices$xGovernment policy$zUnited States
606   $aDrugs$xLaw and legislation$zUnited States
606   $aOrphan drugs$zUnited States
606   $aRare diseases$zUnited States
608   $aLegislative materials.$2lcgft
615  0$aDrug development$xEconomic aspects
615  0$aBuprenorphine$xTherapeutic use
615  0$aOrphan drugs$xGovernment policy
615  0$aDrugs$xPrices$xGovernment policy
615  0$aDrugs$xLaw and legislation
615  0$aOrphan drugs
615  0$aRare diseases
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910715017103321
996   $aFairness in Orphan Drug Exclusivity Act$93527578
997   $aUNINA